Condition: Metastatic Breast Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC). Eligible subjects were randomly assigned in a 1:1 ratio to receive either TQB2102 for injection or trastuzumab emtansine for injection.
This description comes directly from the study's public registry record.
Zhimin Shao, Doctor · 021-64175590 · szm@163.com
Jin Zhang, Doctor · 022-65150123 · zhangjintjmuch1@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Anhui Medical University | Bengbu, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Shunyi Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| The First Hospital Of Lanzhou University | Lanzhou, Gansu, China | Not Yet Recruiting |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | Not Yet Recruiting |
| Affiliated Cancer Hospital Of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| Cancer Hospital Of Guizhou Medical University | Guiyang, Guizhou, China | Not Yet Recruiting |
| Hainan General Hospital | Haikou, Hainan, China | Not Yet Recruiting |
| The Fourth Hospital Of Hebei Medical University | Shijiazhuang, Hebei, China | Not Yet Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07008976